["{\"step_by_step_thinking\": \"There is no direct information about MAGE-A3 immunotherapeutic treatment for non-small-cell lung cancer (NSCLC) in the provided documents. However, one document mentions combination immunotherapy for advanced NSCLC, which implies that immunotherapy can be effective for this type of cancer. Another document discusses adjuvant systemic therapy for lung cancer and mentions immunotherapy as a promising approach. There is also a study on specific active immunochemotherapy in lung cancer that shows improved survival rates in the immunized groups. While these documents do not specifically mention MAGE-A3, they suggest that immunotherapy can be effective for NSCLC. The biology of lung cancer document provides information about autocrine growth factors and molecular advances associated with the pathogenesis of this disease, which may have implications for immunotherapeutic approaches. Overall, it is likely that MAGE-A3 immunotherapeutic treatment could be effective for NSCLC based on the general effectiveness of immunotherapy for this type of cancer.\", \"answer_choice\": \"A\"}"]